Compare EDVA & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDVA | BBLG |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Industrial Specialties |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2M | 1.2M |
| IPO Year | 2012 | 2014 |
| Metric | EDVA | BBLG |
|---|---|---|
| Price | $0.15 | $0.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 44.9K |
| Earning Date | 11-28-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.30 | ★ 45.13 |
| EPS | ★ N/A | N/A |
| Revenue | $73,066.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $24,377.87 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $0.40 |
| 52 Week High | $0.33 | $5.32 |
| Indicator | EDVA | BBLG |
|---|---|---|
| Relative Strength Index (RSI) | 18.69 | 15.45 |
| Support Level | N/A | N/A |
| Resistance Level | $0.18 | $1.18 |
| Average True Range (ATR) | 0.01 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 3.06 | 1.74 |
Endovia Health Sciences Inc is building a diversified cannabinoid health sciences platform through pharmaceutical innovation, strategic partnerships and disciplined execution. Endovia acquires, develops and commercializes differentiated cannabinoid health technologies across pharmaceutical, veterinary and consumer wellness markets. Endovia's product begins with CannEpil, a cannabinoid pharmaceutical asset, and extends into veterinary development and consumer wellness as the pipeline expands.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.